🇺🇸 FDA
Pipeline program

AKCEA-ANGPTL3-LRx

ISIS 703802-CS5

Phase 2 small_molecule completed

Quick answer

AKCEA-ANGPTL3-LRx for Familial Partial Lipodystrophy is a Phase 2 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Familial Partial Lipodystrophy
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials